Merus N.V. announced a public offering of 5,263,158 common shares at $57.00 each, aiming to raise approximately $300 million in gross proceeds. The offering is expected to close on June 5, 2025, pending customary closing conditions. Merus plans to use the proceeds for clinical development and preclinical research, alongside general corporate purposes.
The underwriting group is led by Jefferies and BofA Securities, who also have a 30-day option to purchase an additional 789,473 shares. This offering follows a shelf registration statement filed with the SEC on February 28, 2024.
